ATE512224T1 - Rekonstituierter menschlicher anti-hm.1 antikörper - Google Patents

Rekonstituierter menschlicher anti-hm.1 antikörper

Info

Publication number
ATE512224T1
ATE512224T1 AT97942246T AT97942246T ATE512224T1 AT E512224 T1 ATE512224 T1 AT E512224T1 AT 97942246 T AT97942246 T AT 97942246T AT 97942246 T AT97942246 T AT 97942246T AT E512224 T1 ATE512224 T1 AT E512224T1
Authority
AT
Austria
Prior art keywords
chain
human
antibody
antibodies
region
Prior art date
Application number
AT97942246T
Other languages
English (en)
Inventor
Koichiro Ono
Toshihiko Ohtomo
Masayuki Tsuchiya
Yasushi Yoshimura
Yasuo Koishihara
Masaaki Kosaka
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ATE512224T1 publication Critical patent/ATE512224T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT97942246T 1996-10-04 1997-10-03 Rekonstituierter menschlicher anti-hm.1 antikörper ATE512224T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP26475696 1996-10-04
PCT/JP1997/003553 WO1998014580A1 (en) 1996-10-04 1997-10-03 Reconstituted human anti-hm1.24 antibody

Publications (1)

Publication Number Publication Date
ATE512224T1 true ATE512224T1 (de) 2011-06-15

Family

ID=17407753

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97942246T ATE512224T1 (de) 1996-10-04 1997-10-03 Rekonstituierter menschlicher anti-hm.1 antikörper

Country Status (19)

Country Link
US (2) US6699974B2 (de)
EP (1) EP0960936B1 (de)
KR (1) KR100388256B1 (de)
CN (2) CN1765928A (de)
AT (1) ATE512224T1 (de)
AU (1) AU715156B2 (de)
BR (1) BR9712488A (de)
CA (1) CA2267072C (de)
CZ (1) CZ296790B6 (de)
IL (1) IL129286A0 (de)
NO (1) NO325178B1 (de)
PL (1) PL187642B1 (de)
RU (1) RU2184147C2 (de)
SK (1) SK44399A3 (de)
TR (1) TR199900722T2 (de)
TW (1) TW530064B (de)
UA (1) UA76934C2 (de)
WO (1) WO1998014580A1 (de)
ZA (1) ZA978865B (de)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100655979B1 (ko) 1997-02-12 2006-12-08 츄가이 세이야꾸 가부시키가이샤 임파구계 종양의 치료제
WO1998037913A1 (en) * 1997-02-28 1998-09-03 Chugai Seiyaku Kabushiki Kaisha Lymphocyte activation inhibitors
CN101073667B (zh) 1997-10-14 2013-11-06 中外制药株式会社 淋巴细胞肿瘤抗体的增强剂
JP3609026B2 (ja) * 1998-02-25 2005-01-12 中外製薬株式会社 抗ｈｍ１．２４抗体の免疫化学的測定方法
AU5303699A (en) 1998-09-18 2000-04-10 Chugai Seiyaku Kabushiki Kaisha Method for detecting or measuring plasmocytomas
HK1045715B (zh) * 1999-05-10 2005-06-03 中外制药株式会社 培养细胞的方法
AU784460B2 (en) 1999-08-23 2006-04-06 Chugai Seiyaku Kabushiki Kaisha HM1.24 antigen expression potentiators
AU2001246846A1 (en) * 2000-04-06 2001-10-23 Chugai Seiyaku Kabushiki Kaisha Immunoassay of anti-hm1.24 antibody
US8632778B2 (en) 2000-08-11 2014-01-21 Chugai Seiyaku Kabushiki Kaisha Stabilized anti-interleukin-6 antibody-containing preparations
WO2002057316A1 (en) * 2000-12-28 2002-07-25 Kirin Beer Kabushiki Kaisha Novel monoclonal antibody
EP1364657B1 (de) 2001-02-07 2016-12-28 Chugai Seiyaku Kabushiki Kaisha Mittel gegen myelozytenleukämie
EP3088412B1 (de) 2001-03-09 2021-05-05 Chugai Seiyaku Kabushiki Kaisha Proteinaufreinigungsverfahren
CA2441228A1 (en) * 2001-03-23 2002-10-03 Aphton Corporation Combination treatment of pancreatic cancer
US7776612B2 (en) 2001-04-13 2010-08-17 Chugai Seiyaku Kabushiki Kaisha Method of quantifying antigen expression
US20090191232A1 (en) * 2001-05-04 2009-07-30 Gevas Philip C Combination therapy for the treatment of tumors
ES2312586T3 (es) * 2001-06-22 2009-03-01 Chugai Seiyaku Kabushiki Kaisha Inhibidor del crecimiento celular que contenga un anticuerpo anti-clipicano 3.
KR20040049830A (ko) * 2001-07-09 2004-06-12 애프톤 코포레이션 간, 폐 및 식도의 암 및 전암 상태의 치료 및 예방
WO2003068260A1 (fr) * 2002-02-14 2003-08-21 Chugai Seiyaku Kabushiki Kaisha Produits pharmaceutiques en solution contenant des anticorps
US20080219974A1 (en) * 2002-03-01 2008-09-11 Bernett Matthew J Optimized antibodies that target hm1.24
JP4753578B2 (ja) * 2002-06-03 2011-08-24 ジェネンテック， インコーポレイテッド 合成抗体ファージライブラリー
AU2003257536A1 (en) 2002-08-27 2004-03-19 Chugai Seiyaku Kabushiki Kaisha Method of stabilizing protein solution preparation
EP2261230B1 (de) 2002-09-11 2017-05-10 Chugai Seiyaku Kabushiki Kaisha Verfahren zur Proteinreinigung
CN1781023A (zh) * 2003-03-28 2006-05-31 埃弗顿有限公司 胃泌素激素免疫测定
US20070142627A1 (en) * 2003-08-01 2007-06-21 Chugai Seiyaku Kabushiki Kaisha Sugar-chain-altered anti-hm1.24 antibody
EP1664115A2 (de) * 2003-08-01 2006-06-07 Genentech, Inc. Antikörper cdr polypeptid-sequenzen mit limitierter diversität
EP1693069B1 (de) * 2003-10-10 2013-07-24 Chugai Seiyaku Kabushiki Kaisha Mittel zur behandlung von soliden tumoren
ES2672640T3 (es) * 2003-11-05 2018-06-15 Roche Glycart Ag Moléculas de unión a antígeno con afinidad de unión a receptores Fc y función efectora incrementadas
WO2005080432A2 (en) * 2004-02-19 2005-09-01 Genentech, Inc. Cdr-repaired antibodies
AU2005228897B2 (en) * 2004-03-29 2009-12-10 Cancer Advances, Inc. Monoclonal antibodies to gastrin hormone
JP2008513536A (ja) 2004-09-22 2008-05-01 レセプター バイオロジックス インコーポレイテッド プロガストリンに対するモノクローナル抗体
TWI478940B (zh) * 2005-08-26 2015-04-01 Roche Glycart Ag 具有經改變細胞傳訊活性之改質抗原結合分子
AU2012216702B2 (en) * 2005-08-26 2014-12-04 Roche Glycart Ag Modified antigen binding molecules with altered cell signaling activity
EP1957531B1 (de) 2005-11-07 2016-04-13 Genentech, Inc. Bindungspolypeptide mit diversifizierten und konsensus-vh/vl-hypervariablen sequenzen
EP1973951A2 (de) * 2005-12-02 2008-10-01 Genentech, Inc. Bindende polypeptide mit eingeschränkten diversitätssequenzen
EP1977763A4 (de) 2005-12-28 2010-06-02 Chugai Pharmaceutical Co Ltd Antikörper-enthaltende stabilisierende zubereitung
WO2008036688A2 (en) * 2006-09-18 2008-03-27 Xencor, Inc. Optimized antibodies that target hm1.24
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
RU2595409C2 (ru) 2009-09-03 2016-08-27 Мерк Шарп И Доум Корп., Анти-gitr-антитела
TWI505838B (zh) 2010-01-20 2015-11-01 中外製藥股份有限公司 Stabilized antibody solution containing
WO2013012022A1 (ja) 2011-07-19 2013-01-24 中外製薬株式会社 アルギニンアミドまたはその類似化合物を含む安定なタンパク質含有製剤
CA2847302C (en) 2011-09-01 2021-02-16 Chugai Seiyaku Kabushiki Kaisha Method for preparing a composition comprising highly concentrated antibodies by ultrafiltration
EP4671270A3 (de) 2013-12-27 2026-03-18 Chugai Seiyaku Kabushiki Kaisha Verfahren zur reinigung eines antikörpers mit niedrigem isoelektrischen punkt
EP3185004A4 (de) 2014-08-20 2018-05-30 Chugai Seiyaku Kabushiki Kaisha Verfahren zur messung der viskosität einer proteinlösung
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
JP7469225B2 (ja) 2017-06-15 2024-04-16 キャンサー アドヴァンシーズ インク． 腫瘍及び癌に対する体液性及び細胞性免疫を誘発するための組成物及び方法
US12150978B2 (en) 2017-06-15 2024-11-26 Cancer Advances Inc. Compositions and methods for preventing tumors and cancer
CN109748964B (zh) * 2017-11-01 2020-11-17 深圳宾德生物技术有限公司 CD317单链抗体317scFv、其编码序列及制备方法和应用
WO2019195770A1 (en) 2018-04-06 2019-10-10 Atyr Pharma, Inc. Compositions and methods comprising anti-nrp2 antibodies
CN112512480B (zh) 2018-05-21 2024-10-01 中外制药株式会社 被封入玻璃容器的冷冻干燥制剂
EP3805112A4 (de) 2018-05-28 2022-03-09 Chugai Seiyaku Kabushiki Kaisha Fülldüse
AU2020358854A1 (en) 2019-10-03 2022-05-26 Atyr Pharma, Inc. Compositions and methods comprising anti-NRP2 antibodies
WO2023058723A1 (ja) 2021-10-08 2023-04-13 中外製薬株式会社 プレフィルドシリンジ製剤の調製方法
IL312692A (en) 2021-11-16 2024-07-01 Genentech Inc Methods and compositions for the treatment of systemic lupus erythematosus (SLE) with musontuzumab
WO2023210670A1 (ja) 2022-04-26 2023-11-02 中外製薬株式会社 医薬製剤含有フィルター内蔵シリンジ
EP4696321A1 (de) 2023-04-14 2026-02-18 Chugai Seiyaku Kabushiki Kaisha Verfahren zur stabilisierung einer proteinhaltigen pharmazeutischen zubereitung

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO873164L (no) * 1986-07-30 1988-02-01 Teijin Ltd Muse-humane kimaere antistoffer.
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
GB9014932D0 (en) * 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
ES2134212T3 (es) 1991-04-25 1999-10-01 Chugai Pharmaceutical Co Ltd Anticuerpo humano reconstituido contra el receptor de la interleuquina 6 humano.
CA2195557C (en) * 1994-08-12 2006-10-17 Shui-On Leung Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells
KR100655979B1 (ko) * 1997-02-12 2006-12-08 츄가이 세이야꾸 가부시키가이샤 임파구계 종양의 치료제
US20020034507A1 (en) * 1997-02-28 2002-03-21 Yasuo Koishihara Inhibitor of lymphocyte activation
AU750453B2 (en) * 1997-10-03 2002-07-18 Chugai Seiyaku Kabushiki Kaisha Natural human antibody
CN101073667B (zh) * 1997-10-14 2013-11-06 中外制药株式会社 淋巴细胞肿瘤抗体的增强剂
EP1517921B1 (de) * 2002-06-28 2006-06-07 Domantis Limited Dual-specifische liganden mit erhöhter halbwertszeit

Also Published As

Publication number Publication date
KR20000048884A (ko) 2000-07-25
ZA978865B (en) 1998-04-20
CZ117399A3 (cs) 1999-09-15
CA2267072C (en) 2004-11-30
PL187642B1 (pl) 2004-08-31
CA2267072A1 (en) 1998-04-09
CN1235639A (zh) 1999-11-17
BR9712488A (pt) 1999-10-19
UA76934C2 (en) 2006-10-16
US20030129185A1 (en) 2003-07-10
AU715156B2 (en) 2000-01-20
TR199900722T2 (xx) 1999-12-21
PL332742A1 (en) 1999-10-11
NO325178B1 (no) 2008-02-11
US20030045691A1 (en) 2003-03-06
EP0960936A4 (de) 2005-01-19
CN1765928A (zh) 2006-05-03
WO1998014580A1 (en) 1998-04-09
EP0960936B1 (de) 2011-06-08
NO991591D0 (no) 1999-03-31
EP0960936A1 (de) 1999-12-01
CN1271205C (zh) 2006-08-23
TW530064B (en) 2003-05-01
IL129286A0 (en) 2000-02-17
HK1024261A1 (en) 2000-10-05
CZ296790B6 (cs) 2006-06-14
KR100388256B1 (ko) 2003-06-19
SK44399A3 (en) 2000-05-16
US6699974B2 (en) 2004-03-02
RU2184147C2 (ru) 2002-06-27
AU4399297A (en) 1998-04-24
NO991591L (no) 1999-06-01
US7892543B2 (en) 2011-02-22

Similar Documents

Publication Publication Date Title
ATE512224T1 (de) Rekonstituierter menschlicher anti-hm.1 antikörper
DE69535243D1 (de) Gegen menschliches interleukin-8 gerichteter, rekonstituierter menschlicher antikörper
ATE373712T1 (de) Natürlicher menschlicher antikörper
IL138801A0 (en) Humanized antibody against human tissue factor and process for the preparation thereof
FR12C0004I2 (fr) Anticorps contre l'antigene ctla-4 humain et utilisation
AU692100B2 (en) Reconstituted human antibody against human interleukin 6 receptor
MXPA03009408A (es) Factor de crecimiento endotelial vascular 2.
EP0536275A4 (en) Tissue-derived tumor growth inhibitors, methods of preparation and uses thereof
EP0783525A4 (de) Chimäre mensch-mausantikörper gegen das respiratorische syncytialvirus
ATE166230T1 (de) Verwendung von anti-icam antikörpern zur herstellung eines präparats für die behandlung von endotoxinschock
EP1412388A4 (de) Von dd 3b6/22 abgeleitete humanisierte antikörper mit spezifität für das d-dimer fragment von fibrin
DK0589840T3 (da) Omdannede monoklonale antistoffer mod en immunoglobulinisotype
WO1991010735A3 (fr) Recepteur humain de la tsh. sequence codant pour ce recepteur
SE9201281D0 (sv) New human monoclonal antibodies, and a method for preparation thereof
DE59207362D1 (de) Monoklonale Antikörper gegen den Plasmin-Antiplasmin Komplex, Verfahren zu ihrer Herstellung sowie ihre Verwendung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties